Avalo Therapeutics (AVTX) Common Equity (2016 - 2025)
Avalo Therapeutics (AVTX) has disclosed Common Equity for 12 consecutive years, with $104.6 million as the latest value for Q2 2025.
- For the quarter ending Q2 2025, Common Equity rose 868.47% year-over-year to $104.6 million, compared with a TTM value of $104.6 million through Jun 2025, up 868.47%, and an annual FY2024 reading of $133.0 million, up 1721.36% over the prior year.
- Common Equity was $104.6 million for Q2 2025 at Avalo Therapeutics, down from $122.6 million in the prior quarter.
- Across five years, Common Equity topped out at $133.0 million in Q4 2024 and bottomed at -$112.5 million in Q1 2024.
- Average Common Equity over 5 years is $20.5 million, with a median of $11.0 million recorded in 2023.
- Peak annual rise in Common Equity hit 1721.36% in 2024, while the deepest fall reached 1695.79% in 2024.
- Year by year, Common Equity stood at $23.1 million in 2021, then plummeted by 147.29% to -$10.9 million in 2022, then skyrocketed by 166.92% to $7.3 million in 2023, then skyrocketed by 1721.36% to $133.0 million in 2024, then fell by 21.39% to $104.6 million in 2025.
- Business Quant data shows Common Equity for AVTX at $104.6 million in Q2 2025, $122.6 million in Q1 2025, and $133.0 million in Q4 2024.